Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings Inc (XERS) is a biopharmaceutical innovator developing ready-to-use therapies for complex conditions in endocrinology, neurology, and gastroenterology. This page aggregates official company announcements, regulatory milestones, and research developments for stakeholders tracking its progress.
Access timely updates on XERS' FDA-approved products including Gvoke (severe hypoglycemia), Recorlev (Cushing's Syndrome), and proprietary formulation platforms like XeriSol and XeriJect. Our curated news feed covers clinical trial results, partnership announcements, manufacturing updates, and financial disclosures essential for understanding the company's trajectory in advanced biotherapeutics.
This resource serves investors and healthcare professionals needing verified information about XERS' patient-centric solutions. Content is organized chronologically with clear sourcing to facilitate efficient research. Bookmark this page for structured access to earnings reports, regulatory filings, and scientific advancements from one of biopharma's most innovative formulation specialists.
Xeris Biopharma Holdings (XERS) announced positive topline results from its Phase 1 study of XP-8121, a novel subcutaneous levothyroxine formulation. This study, involving 60 healthy adults, showed that XP-8121 provides similar pharmacokinetics to daily oral Synthroid, offering a potential once-weekly dosing option. The data suggests that a 1200 μg SC dose of XP-8121 could correspond to a 300 μg dose of Synthroid, indicating a 4X dose conversion factor. The treatment was well tolerated, and the company expects FDA feedback by year-end.
Xeris Biopharma achieved record net product revenue of $25.3 million for Q2 2022, reflecting a 15% increase from Q1 2022 and a 34% increase year-over-year on a pro forma basis. The company ended Q2 with $111.6 million in cash and investments, reaffirming a full-year revenue guidance of $105 million to $120 million. Key products such as Gvoke and Keveyis reported strong performances, with Gvoke growing by 30% to $11.5 million in revenue. However, net losses were reported at $26.2 million for the quarter.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will release its second quarter 2022 financial results on August 10, 2022, before U.S. market open. A conference call will follow at 8:30 a.m. ET to discuss the results. The company focuses on developing innovative therapies, with three products currently available: Gvoke®, Keveyis®, and Recorlev®. Xeris aims to expand its product pipeline through proprietary formulation technologies.
Xeris Biopharma Holdings (Nasdaq: XERS) announced that its commercialization partner, Tetris Pharma, will be acquired by Arecor Therapeutics, contingent upon Arecor's successful capital offering. Upon completion, Arecor is set to continue the commercialization of Ogluo in the UK and EEA. The acquisition aims to leverage Arecor's resources to enhance the marketing of Ogluo, a glucagon treatment for severe hypoglycemia in diabetes patients. Xeris will still be responsible for product supply and anticipates a smooth transition of commercial activities.
Xeris Biopharma Holdings (NASDAQ: XERS) presented new findings on Cushing's syndrome (CS) at the AACE Annual Meeting held from May 12-14, 2022. Key highlights include the LOGICS study, a phase 3 trial showing that patients on placebo had a significantly worse mean urinary-free cortisol (mUFC) response than those on Recorlev® (levoketoconazole). Additionally, a burden of illness study indicated that CS patients report moderate impairment in health-related quality of life, with 89% using over-the-counter analgesics for symptom relief. No new safety signals for Recorlev were identified during the study.
Xeris Biopharma Holdings reported Q1 2022 net product revenue of $21.9M, reflecting a 33% increase year-over-year on a pro forma basis. The company ended the quarter with $132.1M in cash and equivalents, affirming 2022 revenue guidance of $105M - $120M and aiming for cash flow breakeven by year-end 2023. Key products like Gvoke achieved over 30,000 prescriptions, a growth of 88%. However, net loss for the quarter stood at $33.7M, compared to $18.4M in Q1 2021.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) will announce its first quarter 2022 financial results before the U.S. market opens on May 11, 2022. A conference call and webcast will follow at 8:30 a.m. ET for investors to discuss the results. Xeris specializes in unique therapies for endocrinology, neurology, and gastroenterology, with three available products: Gvoke®, Keveyis®, and Recorlev®. The company aims to expand its pipeline with novel treatments utilizing its proprietary formulation technologies.
Xeris Biopharma Holdings (Nasdaq: XERS) announced the availability of the Gvoke® Kit, a ready-to-use glucagon injection for severe hypoglycemia, now accessible by prescription. This kit includes a single-dose sterile syringe and vial, designed for those at risk of low blood sugar events. The Gvoke products received FDA approval in September 2019 and August 2021. The company, headquartered in Chicago, aims to meet the growing demand among patients to keep Gvoke readily available for emergencies.
Xeris Biopharma Holdings (XERS) completed the acquisition of Strongbridge Biopharma, realizing $50M in synergies by year-end 2022. Pro forma net product revenues rose to $79M in FY '21, a 56% increase. Expected growth for 2022 is $105M-$120M with cash resources projected at $90M-$110M by year-end. The company anticipates reaching cash flow breakeven by the end of 2023. Key product sales, including Gvoke and Recorlev, are driving growth, alongside a strong cash position bolstered by recent financing moves.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has secured a $150 million senior secured term loan from Hayfin Capital Management. The initial drawdown of $100 million will repay existing debts and enhance working capital. Xeris aims for cash flow breakeven by year-end 2023, leveraging a total capital base of approximately $180 million. The debt facility has a five-year maturity with a 9% interest rate and provides additional borrowing flexibility. Xeris' CFO noted this agreement increases financial strength while protecting shareholder interests through non-dilutive capital.
